围产期HIV感染青少年外周血单核细胞前病毒DNA中M184V与K65R耐药突变流行率
该研究分析了接受拉米夫定/恩曲他滨治疗且病毒学抑制的围产期HIV感染青少年,其外周血单核细胞前病毒DNA中M184V/I和/或K65R/E/N突变的流行率。在225例随访患者中,13例符合入选标准,12例成功扩增逆转录酶序列。结果显示,75%的青少年在病毒抑制至少1年后前病毒DNA中未检出M184V/I,提示既往耐药者仍可安全使用拉米夫定或恩曲他滨。
要点
- 病毒学抑制的围产期HIV感染青少年中,前病毒DNA耐药突变流行率低。
- 75%有既往耐药史者在抑制至少1年后前病毒DNA中M184V/I消失。
- 既往对拉米夫定/恩曲他滨耐药者仍可考虑含该药的方案。
核心结论
- 在病毒学抑制的围产期HIV感染青少年中,前病毒DNA中拉米夫定和恩曲他滨耐药突变流行率低。
- 既往血浆检出耐药者仍可安全成功使用含拉米夫定或恩曲他滨的方案。
研究设计与样本
- 来自马德里HIV感染儿童和青少年队列的垂直感染青少年/年轻成人,年龄≥10岁。
- 入选条件:既往暴露于拉米夫定和/或恩曲他滨,历史血浆样本有M184V/I和/或K65R/E/N,正在接受抗逆转录病毒治疗且病毒学抑制(HIV-1 RNA<50拷贝/mL),并有可用的外周血单核细胞。
- 从外周血单核细胞提取基因组DNA,扩增HIV-1逆转录酶基因并用Stanford HIV Resistance工具测序分析耐药。
- 225例随访患者中13例(5.8%)符合标准,12例(92.3%)成功获得逆转录酶序列。
主要发现
- 12例中除1例外均为西班牙人,携带B亚型,外周血单核细胞采样中位年龄21.3岁(IQR 15.6-23.1),病毒载量抑制中位时间4年(IQR 2.1-6.5)。
- 9例(75%)青少年在病毒抑制至少1年后前病毒DNA中未检出M184V/I。
- 截至2019年12月,剩余3例前病毒DNA携带M184V/I者维持病毒血症抑制,其中2例仍在抗逆转录病毒治疗中使用恩曲他滨。
临床怎么用
- 对于有拉米夫定/恩曲他滨耐药史但当前病毒学抑制的围产期HIV感染青少年,含拉米夫定或恩曲他滨的方案可能安全有效。
- 前病毒DNA耐药检测可辅助评估既往耐药突变存档情况,但耐药突变可能随时间消失。
局限性
- 样本量小(仅12例获得序列),结论需更大队列验证。
- 仅纳入病毒学抑制且外周血单核细胞可用的患者,可能存在选择偏倚。
- 前病毒DNA耐药检测未覆盖全部耐药位点,且未评估突变对临床结局的长期影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We analysed the prevalence of M184V/I and/or K65R/E/N mutations archived in proviral DNA (pDNA) in youths with perinatal HIV, virological control and who previously carried these resistance mutations in historic plasma samples. METHODS: We included vertically HIV-infected youths/young adults aged ≥10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), and with available PBMCs in the Spanish HIV BioBank. Genomic DNA was extracted from PBMCs and HIV-1 RT gene was amplified and sequenced for resistance testing by Stanford HIV Resistance tool. RESULTS: Among the 225 patients under follow-up in the study cohort, 13 (5.8%) met selection criteria, and RT sequences were recovered in 12 (92.3%) of them. All but one were Spaniards, carrying subtype B, with a median age at PBMCs sampling of 21.3 years (IQR: 15.6-23.1) with 4 years (IQR 2.1-6.5) of suppressed viral load (VL). Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression. In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART. CONCLUSIONS: The prevalence of resistance mutations to lamivudine and emtricitabine in pDNA in a cohort of youths perinatally infected with HIV who remain with undetectable VL, previously lamivudine and/or emtricitabine experienced, was infrequent. Our results indicate that ART including lamivudine or emtricitabine may also be safe and successful in youths with perinatal HIV with previous experience of and resistances to these drugs detected in plasma.
引用
- Jiménez de Ory S, Beltrán-Pavez C, Gutiérrez-López M, et al. Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure. J Antimicrob Chemother. 2021. PMID: 33734374. doi:10.1093/jac/dkab080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。